SE0303091D0 - Combined doses of tiotropium andfluticasone - Google Patents
Combined doses of tiotropium andfluticasoneInfo
- Publication number
- SE0303091D0 SE0303091D0 SE0303091A SE0303091A SE0303091D0 SE 0303091 D0 SE0303091 D0 SE 0303091D0 SE 0303091 A SE0303091 A SE 0303091A SE 0303091 A SE0303091 A SE 0303091A SE 0303091 D0 SE0303091 D0 SE 0303091D0
- Authority
- SE
- Sweden
- Prior art keywords
- combined doses
- metered
- doses
- medicinal
- medicaments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0066—Inhalators with dosage or measuring devices with means for varying the dose size
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Abstract
The present invention discloses a method and pharmaceutical dry powder combined doses for administration by inhalation of metered dry powder combined doses of finely divided dry medication doses. Tiotropium and fluticasone are selected medicaments for forming the combined doses. Metered dry powder medicinal combined doses comprising separately metered deposits of medicinally effective quantities of each of the selected medicaments are prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined doses and the medicinal combined doses are introduced into an adapted inhaler device for a generally simultaneous or sequential prolonged delivery of the medicinal combined doses during the course of a single inhalation by a user, such that each one of the administered medicinal combined doses is composed of a high proportion of de-aggregated fine particles of the selected medicament or medicaments and directed to a selected location in the lungs.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0303091A SE527191C2 (en) | 2003-06-19 | 2003-11-18 | Inhaler device and combined doses of tiotropium and fluticasone |
CA002529127A CA2529127A1 (en) | 2003-06-19 | 2004-06-15 | Combined doses of tiotropium and fluticasone |
AU2004246990A AU2004246990A1 (en) | 2003-06-19 | 2004-06-15 | Combined doses of tiotropium and fluticasone |
PCT/SE2004/000954 WO2004110404A1 (en) | 2003-06-19 | 2004-06-15 | Combined doses of tiotropium and fluticasone |
EP04749003A EP1696882A1 (en) | 2003-06-19 | 2004-06-15 | Combined doses of tiotropium and fluticasone |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0301816A SE526850C2 (en) | 2003-06-19 | 2003-06-19 | Pharmaceutical combined dry powder dose separated on common dose bed |
US50026203P | 2003-09-05 | 2003-09-05 | |
SE0303091A SE527191C2 (en) | 2003-06-19 | 2003-11-18 | Inhaler device and combined doses of tiotropium and fluticasone |
Publications (3)
Publication Number | Publication Date |
---|---|
SE0303091D0 true SE0303091D0 (en) | 2003-11-18 |
SE0303091L SE0303091L (en) | 2004-12-20 |
SE527191C2 SE527191C2 (en) | 2006-01-17 |
Family
ID=29740585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0303091A SE527191C2 (en) | 2003-06-19 | 2003-11-18 | Inhaler device and combined doses of tiotropium and fluticasone |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1696882A1 (en) |
AU (1) | AU2004246990A1 (en) |
CA (1) | CA2529127A1 (en) |
SE (1) | SE527191C2 (en) |
WO (1) | WO2004110404A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070101991A1 (en) * | 2005-11-08 | 2007-05-10 | Mederio Ag | Optimizing release of dry medicament powder |
LT2400950T (en) | 2009-02-26 | 2019-08-26 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
WO2011093813A1 (en) * | 2010-01-28 | 2011-08-04 | Mahmut Bilgic | Dry powder pharmaceutical composition comprising tiotropium and fluticasone |
US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
TR201000733A2 (en) * | 2010-02-02 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate. |
WO2012093252A1 (en) | 2011-01-06 | 2012-07-12 | Cipla Limited | Pharmaceutical composition |
JOP20120023B1 (en) | 2011-02-04 | 2022-03-14 | Novartis Ag | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
KR20140041699A (en) * | 2011-06-08 | 2014-04-04 | 글락소 그룹 리미티드 | Combination comprising umeclidinium and a corticosteroid |
WO2013153146A1 (en) | 2012-04-13 | 2013-10-17 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI108518B (en) * | 1999-04-23 | 2002-02-15 | Orion Yhtymae Oyj | Powder inhaler for combination medicine |
FI107126B (en) * | 1999-04-23 | 2001-06-15 | Orion Yhtymae Oyj | Powder inhaler for combination medicine |
GB9920839D0 (en) * | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
GB9928265D0 (en) * | 1999-12-01 | 2000-01-26 | Innovata Biomed Ltd | Inhaler |
GB0009591D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical combinations |
SE517229C2 (en) * | 2000-09-25 | 2002-05-14 | Microdrug Ag | Continuous dry powder inhaler |
US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
DE60234825D1 (en) * | 2001-04-19 | 2010-02-04 | Technology Innovation Ltd | DRUGS CONTAINER |
GB0201677D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
EP1467790A1 (en) * | 2002-01-25 | 2004-10-20 | Glaxo Group Limited | Medicament dispenser |
-
2003
- 2003-11-18 SE SE0303091A patent/SE527191C2/en not_active IP Right Cessation
-
2004
- 2004-06-15 EP EP04749003A patent/EP1696882A1/en not_active Withdrawn
- 2004-06-15 CA CA002529127A patent/CA2529127A1/en not_active Abandoned
- 2004-06-15 WO PCT/SE2004/000954 patent/WO2004110404A1/en active Application Filing
- 2004-06-15 AU AU2004246990A patent/AU2004246990A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SE527191C2 (en) | 2006-01-17 |
CA2529127A1 (en) | 2004-12-23 |
EP1696882A1 (en) | 2006-09-06 |
SE0303091L (en) | 2004-12-20 |
WO2004110404A1 (en) | 2004-12-23 |
AU2004246990A1 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110625T1 (en) | METHOD OF ADMINISTRATION OF TYTOTROP | |
EE04803B1 (en) | Multidose inhalation device in powder form for drug administration | |
DE60013800D1 (en) | POWDER INHALATOR FOR A COMBINED MEDICINE | |
NO20015083L (en) | Combined medicine inhaler | |
EA200802012A1 (en) | PHARMACEUTICAL PREPARATIONS IN THE FORM OF SOLUTION FOR DOSING INHALERS UNDER PRESSURE | |
BR9510647A (en) | Medicine inhaler. | |
SE0303050D0 (en) | Conbined doses | |
KR20010020346A (en) | Method of delivering halotherapy | |
SE0301815L (en) | Administration of medicinal dry powders | |
SE0303091D0 (en) | Combined doses of tiotropium andfluticasone | |
DE60135099D1 (en) | powder inhaler | |
SE0302939D0 (en) | Combined doses of formoterol and fluticasone | |
TW200602054A (en) | Use of compounds in a dry powder inhaler | |
SE0303128D0 (en) | Combined doses of formoterol and an anticholinergic agent | |
SE0301816D0 (en) | Combined doses | |
SE0303375D0 (en) | Combined doses of formoterol and budesonide | |
WO2001062264A3 (en) | Halotherapy method by inhalation of sodium chloride | |
RU2258539C1 (en) | Powder inhaler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |